查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
炎症性腸綜合症治療市場 - 預測 2023-2028
市場調查報告書
商品編碼
1279593

炎症性腸綜合症治療市場 - 預測 2023-2028

Inflammatory Bowel Syndrome Treatment Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

炎症性腸綜合徵 (IBS) 治療市場預計 2021 年價值為 225.29 億美元，在預測期內出現強勁增長。 炎症性腸綜合徵是一種慢性胃腸道疾病，會影響大腸（結腸）並引起腹痛、腹脹、腹瀉和便秘等症狀。 這是一種複雜的疾病，尚無確定的治療方法，其確切原因尚不清楚。 因此，IBS 行業提供了多種旨在控製或減輕這種症狀的藥物和治療方法。 這些治療大致分為兩種類型：藥物治療和非藥物治療。 瀉藥、止瀉藥、解痙藥和抗抑鬱藥只是藥理上用於治療腸易激綜合徵的少數藥物。 通過關注特定的腸易激綜合症症狀，例如腸收縮力下降、排便頻率增加和情緒升高，這些藥物可以減輕症狀。

飲食改變（例如增加纖維攝入量和避免某些觸發食物）和生活方式改變（例如壓力管理和鍛煉）是 IBS 非藥物治療的例子。 補充或替代治療包括針灸和催眠療法，一些患者可能會發現這些療法有用。 新型創新療法的開發、患病率的上升以及患者和醫療保健專業人員對 IBS 認識的提高預計將在未來幾年推動 IBS 治療市場的增長。 然而，市場也必鬚麵對一些問題，例如一些藥品價格高，以及目前的治療方法對一些患者無效等。

炎症性腸綜合徵藥物市場是由 IBS 病例數量和認識以及診斷方法的引入和改進所驅動的。

  • 炎症性腸綜合徵患病率的上升是推動 IBS 治療市場的主要因素之一，並受到飲食、生活方式和腸道微生物群變化等多種變量的推動。 也有人指出，腸道菌群的變化與IBS的發病以及這些生活習慣有關。 根據美國國家糖尿病、消化和腎臟疾病研究所 (NIDDK) 的數據，IBS 影響著 25 至 4500 萬美國人。 提高患者和醫療保健專業人員對 IBS 的認識也是推動 IBS 藥物市場的關鍵因素。 對這個問題的深入了解可以導致更早的診斷和治療，從而改善患者的治療結果。 診斷技術的改進也促進了 IBS 治療市場的增長，從而提高了診斷 IBS 的準確性和效率。 近年來開發了幾種診斷測試來幫助確診腸易激綜合症並排除可能出現類似症狀的其他疾病。 例如，美國胃腸病學會建議使用某些診斷方法（例如結腸鏡檢查和糞便鈣衛蛋白測定）來診斷 IBS。 此外，2020 年，美國食品和藥物管理局 (FDA) 批准替那醇用於治療成人便秘 IBS。

市場增長的主要挑戰是治療成本高昂以及治療解決方案的知識和效率有限。

許多現有的 IBS 治療方法僅部分有效，導致許多患者的症狀緩解不充分。 例如，解痙藥和抗抑鬱藥具有顯著的副作用，在用於治療腸易激綜合症時可能會限制其耐受性。 此外，一些較新的 IBS 治療方法（例如生物製劑）價格昂貴，並且對某些患者來說可能難以獲得。 這些原因都極大地阻礙了IBS藥物市場的發展。

亞太地區和北美在炎症性腸綜合徵藥物市場中佔據很大份額。

炎症性腸綜合徵治療市場按地理位置劃分為北美、南美、歐洲、中東和非洲以及亞太地區。 由於IBS發病率高且擁有許多大型製藥公司，北美預計將在IBS全球市場中佔據很大份額。 據加拿大腸病學會稱，IBS 估計影響 5% 至 20% 的加拿大人。 此外，該地區擁有發達的醫療基礎設施和高水平的腸易激綜合症一般和專業知識。 因此，開發針對這種疾病的新穎且創造性的治療方法已成為當務之急。

由於該地區人口龐大且不斷增長，以及該疾病患病率不斷上升，預計亞太地區 IBS 治療市場將大幅增長。 此外，腸易激綜合症在該地區變得越來越廣為人知，增加了對診斷和治療方案的需求。 此外，許多大型製藥公司已向該地區擴張，加大研發投入。

內容

第 1 章簡介

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場細分
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表

第 2 章研究方法

  • 調查數據
  • 調查設計
  • 驗證

第 3 章執行摘要

  • 調查要點

第 4 章市場動態

  • 市場促進因素
  • 市場抑制因素
  • 波特五力分析
  • 行業價值鏈分析

第 5 章炎症性腸綜合症藥物市場：按類型

  • 簡介
  • 伴有腹瀉的炎症性腸綜合症 (IBS-D)
  • 伴有便秘的炎症性腸綜合症 (IBS-C)
  • 感染後 IBS (IBS-PI)
  • 其他

第 6 章炎症性腸綜合症藥物市場：按治療類型劃分

  • 簡介
  • 醫學
  • 心理治療
  • 膳食補充劑
  • 其他

第 7 章炎症性腸綜合症藥物市場：按地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙特阿拉伯
    • 以色列
    • 阿拉伯聯合酋長國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞
    • 越南
    • 印度尼西亞
    • 其他

第 8 章競爭格局與分析

  • 主要公司及戰略分析
  • 新興公司和市場盈利能力
  • 合併、收購、協議與合作
  • 供應商競爭力矩陣

第 9 章公司簡介

  • AbbVie Inc.
  • Ironwood Pharmaceuticals
  • Bayer AG
  • Probi AB
  • Salix Pharmaceuticals
  • Cosmo Pharmaceuticals
簡介目錄
Product Code: KSI061614661

The inflammatory bowel syndrome (IBS) treatment market was valued at US$22.529 billion in 2021 and will witness robust growth over the projected period. Inflammatory bowel syndrome is a chronic digestive disorder that affects the large intestine (colon) and causes symptoms such as abdominal pain, bloating, diarrhea, and constipation. It is a complicated illness with no known cure, and its precise cause is unclear. As a result, the IBS industry offers various medications and therapies designed to control and lessen the condition's symptoms. The two primary categories of these treatments are pharmacological and non-pharmacological. Laxatives, anti-diarrheal medicines, antispasmodics, and antidepressants are a few examples of the pharmaceuticals used pharmacologically to treat IBS. By focusing on particular IBS symptoms, such as decreased bowel contractions, increased frequency of stools, or mood enhancement, these drugs seek to alleviate the symptoms of the condition.

Dietary changes, such as increasing fiber intake or avoiding particular trigger foods, and lifestyle improvements, such as stress management and exercise, are examples of non-pharmacological therapy for IBS. Additional treatment options like supplementary and alternative therapies include acupuncture or hypnosis, which some patients may find helpful. The development of novel and innovative treatments, the rising prevalence of the illness, rising awareness of IBS among patients and healthcare professionals, and other factors are projected to fuel the growth of the IBS treatment market in the upcoming years. However, the market also has to contend with issues like the high cost of some pharmaceuticals and the ineffectiveness of some patients' present treatments.

The inflammatory bowel syndrome treatment market is driven by the rising cases and awareness of IBS and by the introduction and improvements in diagnostic procedures.

  • The rising prevalence of inflammatory bowel syndrome is one of the main factors driving the IBS treatment market, which is caused by various variables such as changes in food, lifestyle, and gut microbiota. Changes in gut flora have also been linked to the development of IBS and these lifestyle factors. IBS affects between 25 and 45 million Americans, according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
  • Increasing awareness of IBS among patients and healthcare professionals is another important factor driving the IBS treatment market. Advanced knowledge of the issue may result in earlier diagnosis and treatment, improving patient outcomes.
  • Improvements in diagnostic technology are also fuelling the growth of the IBS treatment market, which increases the precision and efficiency of IBS diagnosis. Recent years have seen the development of several diagnostic tests that can help confirm an IBS diagnosis and rule out other illnesses that might present with comparable symptoms. For example, the American College of Gastroenterology suggests using certain diagnostic procedures to diagnose IBS, including colonoscopies and fecal calprotectin assays. The U.S. Food and Drug Administration (FDA) also approved tenapanor in 2020 for treating IBS with constipation in adults.

The key challenges to the market growth are high-cost treatments and limited knowledge and efficiency of treatment solutions.

Since many available IBS treatments are only partially effective, many patients only get insufficient symptom relief. Antispasmodics and antidepressants, for example, might have considerable adverse effects that restrict their acceptability when used as IBS therapy. In addition, some of the more recent IBS medications, such as biologics, can be pricey, which limits some patients' access to them. These reasons significantly hamper the development of the IBS treatment market.

Market Developments

  • In May 2022, the Indian Council of Medical Research (ICMR) released the IBD NutriCare App for patients suffering from inflammatory bowel disease (IBD). The ICMR, a group of gastroenterologists, dieticians, and app developers from AIIMS, collaborated to create the IBD NutriCare App targeted at the IBD population in India. It offers real-time data that informs the nutritionist or dietician about compliance problems, inaccurate entries, and inaccurate information, assisting in launching early and prompt nutritional interventions and creating individualized diet programs. It is mainly concentrated on the ease of large-scale data collecting and personalized tele-nutrition counseling that can improve the general clinical practice of dietary control and nutrition in IBD in a resource-constrained country like India.

Asia Pacific and North America accounted for a major share of the inflammatory bowel syndrome treatment market.

The inflammatory bowel syndrome treatment market is segmented geographically into North America, South America, Europe, Middle East and Africa, and Asia Pacific. North America is anticipated to control significant shares of the global IBS market due to the region's high incidence of the ailment and numerous big pharmaceutical companies. According to the Canadian Society of Intestinal Research, IBS is estimated to affect between 5% and 20% of Canadians. Additionally, the region has a strong healthcare infrastructure and high public and professional knowledge of IBS. As a result, developing novel and creative remedies for the illness has become a priority.

The Asia Pacific IBS treatment market is predicted to rise significantly due to the region's huge and expanding population and the ailment's rising prevalence. IBS is also becoming more widely known in the area, which has boosted the demand for diagnostic procedures and treatment alternatives. A number of significant pharmaceutical companies have also established operations in the area, which has increased investment in R&D.

Market Segmentation

By Type

  • Irritable Bowel Syndrome with Diarrhea (IBS-D)
  • Irritable Bowel Syndrome with Constipation (IBS-C)
  • Post-infectious IBS (IBS-PI)
  • Others

By Treatment Type

  • Medications
  • Psychological Therapy
  • Dietary Supplements
  • Others

By Geography

  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • UAE
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Vietnam
    • Indonesia
    • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Research Design
  • 2.3. Validation

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. INFLAMMATORY BOWEL SYNDROME TREATMENT MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Inflammatory Bowel Syndrome with Diarrhea (IBS-D)
  • 5.3. Inflammatory Bowel Syndrome with Constipation (IBS-C)
  • 5.4. Post-infectious IBS (IBS-PI)
  • 5.5. Others

6. INFLAMMATORY BOWEL SYNDROME TREATMENT MARKET BY TREATMENT TYPE

  • 6.1. Introduction
  • 6.2. Medications
  • 6.3. Psychological Therapy
  • 6.4. Dietary Supplements
  • 6.5. Others

7. INFLAMMATORY BOWEL SYNDROME TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East And Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. UAE
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. Japan
    • 7.6.3. India
    • 7.6.4. South Korea
    • 7.6.5. Australia
    • 7.6.6. Vietnam
    • 7.6.7. Indonesia
    • 7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisition, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. AbbVie Inc.
  • 9.2. Ironwood Pharmaceuticals
  • 9.3. Bayer AG
  • 9.4. Probi AB
  • 9.5. Salix Pharmaceuticals
  • 9.6. Cosmo Pharmaceuticals

Not an exhaustive list